Cynata Therapeutics Ltd has released a press release.
Cynata signs Licence Agreement with TekCyte
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- First Patient Enrolled in Cynata MEND Clinical Trial
- Cynata Therapeutics Expands MEND clinical trial in COVID-19 and Respiratory Failure
- Cynata Expands trial in COVID-19 & Respiratory Failure
- New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs
- Cynata Therapeutics Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte
Later from Cynata Therapeutics
- Progress Toward Clinical Trial in Diabetic Foot Ulcers
- Ethics Approval for Cynatas Clinical Trial in DFU
- Cynata Receives Notice of Allowance from US Patent Office
- Further Canadian Patent for Cynata
- Further Patents for Cynata Unique Cymerus Technology
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics